Optionsscheine finden
Nähere Informationen zum Handelssegment EASY EUWAX finden Sie hier.
► Tipp: Abonnieren Sie unsere Newsletter, um immer auf dem Laufenden bei aktuellen Wertpapierentwicklungen zu bleiben.
Ihre Auswahl:
112 Ergebnisse
| MN6DYF |  | Halozyme Therapeutics Inc./OS/Call [75]/MS | - | - | 75,000 | call | Halozyme Therapeutics Inc. | - | 52,965 % | 0,690 | -0,019 | 3,097 | 19.03.2027 | 0,100 | Morgan Stanley | |
| JZ9Y2M | Halozyme Therapeutics Inc./OS/Call [76]/JPMD | - | - | 76,000 | call | Halozyme Therapeutics Inc. | - | 51,642 % | 0,692 | -0,037 | 5,653 | 18.09.2026 | 0,100 | JP Morgan | ||
| JE0YPD | Halozyme Therapeutics Inc./OS/Call [76]/JPMD | - | - | 76,000 | call | Halozyme Therapeutics Inc. | - | 54,206 % | 0,670 | -0,025 | 3,737 | 18.12.2026 | 0,100 | JP Morgan | ||
| JZ91T3 | Halozyme Therapeutics Inc./OS/Call [78]/JPMD | - | - | 78,000 | call | Halozyme Therapeutics Inc. | - | 49,252 % | 0,652 | -0,037 | 6,180 | 18.09.2026 | 0,100 | JP Morgan | ||
| JE111M | Halozyme Therapeutics Inc./OS/Call [78]/JPMD | - | - | 78,000 | call | Halozyme Therapeutics Inc. | - | 53,641 % | 0,643 | -0,025 | 3,884 | 18.12.2026 | 0,100 | JP Morgan | ||
| JZ97TL | Halozyme Therapeutics Inc./OS/Call [80]/JPMD | - | - | 80,000 | call | Halozyme Therapeutics Inc. | - | 47,719 % | 0,600 | -0,037 | 6,741 | 18.09.2026 | 0,100 | JP Morgan | ||
| JE111P | Halozyme Therapeutics Inc./OS/Call [80]/JPMD | - | - | 80,000 | call | Halozyme Therapeutics Inc. | - | 50,456 % | 0,614 | -0,024 | 4,206 | 18.12.2026 | 0,100 | JP Morgan | ||
| JY2PZL | Halozyme Therapeutics Inc./OS/Call [80]/JPMD | - | - | 80,000 | call | Halozyme Therapeutics Inc. | - | 65,786 % | 0,596 | -0,071 | 6,925 | 21.08.2026 | 0,100 | JP Morgan | ||
| MM26P4 | | Halozyme Therapeutics Inc./OS/Call [80]/MS | - | - | 80,000 | call | Halozyme Therapeutics Inc. | - | 50,511 % | 0,614 | -0,024 | 4,204 | 18.12.2026 | 0,100 | Morgan Stanley | |
| MM26P3 | | Halozyme Therapeutics Inc./OS/Call [80]/MS | - | - | 80,000 | call | Halozyme Therapeutics Inc. | - | 52,929 % | 0,648 | -0,017 | 2,882 | 17.06.2027 | 0,100 | Morgan Stanley | |
| MM5J5Z | | Halozyme Therapeutics Inc./OS/Call [80]/MS | - | - | 80,000 | call | Halozyme Therapeutics Inc. | - | 48,065 % | 0,603 | -0,037 | 6,677 | 18.09.2026 | 0,100 | Morgan Stanley | |
| MN030Y | | Halozyme Therapeutics Inc./OS/Call [80]/MS | - | - | 80,000 | call | Halozyme Therapeutics Inc. | - | 61,077 % | 0,683 | -0,015 | 2,186 | 17.12.2027 | 0,100 | Morgan Stanley | |
| MN6DYG | | Halozyme Therapeutics Inc./OS/Call [80]/MS | - | - | 80,000 | call | Halozyme Therapeutics Inc. | - | 51,807 % | 0,632 | -0,020 | 3,348 | 19.03.2027 | 0,100 | Morgan Stanley | |
| JE04WR | Halozyme Therapeutics Inc./OS/Call [82]/JPMD | - | - | 82,000 | call | Halozyme Therapeutics Inc. | - | 46,241 % | 0,555 | -0,037 | 7,281 | 18.09.2026 | 0,100 | JP Morgan | ||
| JE111L | Halozyme Therapeutics Inc./OS/Call [82]/JPMD | - | - | 82,000 | call | Halozyme Therapeutics Inc. | - | 49,553 % | 0,588 | -0,024 | 4,383 | 18.12.2026 | 0,100 | JP Morgan | ||
| JE0D0P | Halozyme Therapeutics Inc./OS/Call [84]/JPMD | - | - | 84,000 | call | Halozyme Therapeutics Inc. | - | 48,193 % | 0,497 | -0,038 | 7,457 | 18.09.2026 | 0,100 | JP Morgan | ||
| JE0YP9 | Halozyme Therapeutics Inc./OS/Call [84]/JPMD | - | - | 84,000 | call | Halozyme Therapeutics Inc. | - | 49,781 % | 0,554 | -0,024 | 4,525 | 18.12.2026 | 0,100 | JP Morgan | ||
| JY2PZU | Halozyme Therapeutics Inc./OS/Call [85]/JPMD | - | - | 85,000 | call | Halozyme Therapeutics Inc. | - | 54,763 % | 0,450 | -0,060 | 9,554 | 21.08.2026 | 0,100 | JP Morgan | ||
| MM2SE3 | | Halozyme Therapeutics Inc./OS/Call [85]/MS | - | - | 85,000 | call | Halozyme Therapeutics Inc. | - | 52,080 % | 0,600 | -0,017 | 3,058 | 17.06.2027 | 0,100 | Morgan Stanley | |
| MM2SE0 | | Halozyme Therapeutics Inc./OS/Call [85]/MS | - | - | 85,000 | call | Halozyme Therapeutics Inc. | - | 50,301 % | 0,542 | -0,025 | 4,541 | 18.12.2026 | 0,100 | Morgan Stanley | |
| MM5J60 | | Halozyme Therapeutics Inc./OS/Call [85]/MS | - | - | 85,000 | call | Halozyme Therapeutics Inc. | - | 51,752 % | 0,483 | -0,040 | 7,105 | 18.09.2026 | 0,100 | Morgan Stanley | |
| MN030Z | | Halozyme Therapeutics Inc./OS/Call [85]/MS | - | - | 85,000 | call | Halozyme Therapeutics Inc. | - | 60,128 % | 0,650 | -0,015 | 2,275 | 17.12.2027 | 0,100 | Morgan Stanley | |
| MN7LDD | | Halozyme Therapeutics Inc./OS/Call [85]/MS | - | - | 85,000 | call | Halozyme Therapeutics Inc. | - | 51,186 % | 0,575 | -0,020 | 3,576 | 19.03.2027 | 0,100 | Morgan Stanley | |
| JZ9ZEA | Halozyme Therapeutics Inc./OS/Call [86]/JPMD | - | - | 86,000 | call | Halozyme Therapeutics Inc. | - | 47,263 % | 0,445 | -0,037 | 8,011 | 18.09.2026 | 0,100 | JP Morgan | ||
| JE0YPE | Halozyme Therapeutics Inc./OS/Call [86]/JPMD | - | - | 86,000 | call | Halozyme Therapeutics Inc. | - | 52,281 % | 0,534 | -0,026 | 4,434 | 18.12.2026 | 0,100 | JP Morgan | ||
| JE0V86 | Halozyme Therapeutics Inc./OS/Call [88]/JPMD | - | - | 88,000 | call | Halozyme Therapeutics Inc. | - | 47,737 % | 0,403 | -0,036 | 8,300 | 18.09.2026 | 0,100 | JP Morgan | ||
| JE111F | Halozyme Therapeutics Inc./OS/Call [88]/JPMD | - | - | 88,000 | call | Halozyme Therapeutics Inc. | - | 52,117 % | 0,506 | -0,026 | 4,570 | 18.12.2026 | 0,100 | JP Morgan | ||
| JE0YP7 | Halozyme Therapeutics Inc./OS/Call [90]/JPMD | - | - | 90,000 | call | Halozyme Therapeutics Inc. | - | 52,007 % | 0,473 | -0,025 | 4,727 | 18.12.2026 | 0,100 | JP Morgan | ||
| JY10S1 | Halozyme Therapeutics Inc./OS/Call [90]/JPMD | - | - | 90,000 | call | Halozyme Therapeutics Inc. | - | 48,485 % | 0,358 | -0,035 | 8,584 | 18.09.2026 | 0,100 | JP Morgan | ||
| JY2E1G | Halozyme Therapeutics Inc./OS/Call [90]/JPMD | - | - | 90,000 | call | Halozyme Therapeutics Inc. | - | 59,909 % | 0,322 | -0,058 | 10,088 | 21.08.2026 | 0,100 | JP Morgan | ||
| MM26P5 | | Halozyme Therapeutics Inc./OS/Call [90]/MS | - | - | 90,000 | call | Halozyme Therapeutics Inc. | - | 51,387 % | 0,552 | -0,017 | 3,230 | 17.06.2027 | 0,100 | Morgan Stanley | |
| MM26P6 | | Halozyme Therapeutics Inc./OS/Call [90]/MS | - | - | 90,000 | call | Halozyme Therapeutics Inc. | - | 49,799 % | 0,466 | -0,024 | 4,933 | 18.12.2026 | 0,100 | Morgan Stanley | |
| MM5J61 | | Halozyme Therapeutics Inc./OS/Call [90]/MS | - | - | 90,000 | call | Halozyme Therapeutics Inc. | - | 52,993 % | 0,377 | -0,039 | 7,764 | 18.09.2026 | 0,100 | Morgan Stanley | |
| MN0310 | | Halozyme Therapeutics Inc./OS/Call [90]/MS | - | - | 90,000 | call | Halozyme Therapeutics Inc. | - | 58,778 % | 0,618 | -0,015 | 2,376 | 17.12.2027 | 0,100 | Morgan Stanley | |
| MN6DYH | | Halozyme Therapeutics Inc./OS/Call [90]/MS | - | - | 90,000 | call | Halozyme Therapeutics Inc. | - | 50,401 % | 0,517 | -0,020 | 3,831 | 19.03.2027 | 0,100 | Morgan Stanley | |
| JE111C | Halozyme Therapeutics Inc./OS/Call [92]/JPMD | - | - | 92,000 | call | Halozyme Therapeutics Inc. | - | 51,825 % | 0,447 | -0,025 | 4,867 | 18.12.2026 | 0,100 | JP Morgan | ||
| JY10S2 | Halozyme Therapeutics Inc./OS/Call [92]/JPMD | - | - | 92,000 | call | Halozyme Therapeutics Inc. | - | 48,887 % | 0,320 | -0,033 | 8,873 | 18.09.2026 | 0,100 | JP Morgan | ||
| JE111E | Halozyme Therapeutics Inc./OS/Call [94]/JPMD | - | - | 94,000 | call | Halozyme Therapeutics Inc. | - | 52,062 % | 0,421 | -0,025 | 4,969 | 18.12.2026 | 0,100 | JP Morgan | ||
| MM3GSJ | | Halozyme Therapeutics Inc./OS/Call [95]/MS | - | - | 95,000 | call | Halozyme Therapeutics Inc. | - | 50,557 % | 0,509 | -0,017 | 3,404 | 17.06.2027 | 0,100 | Morgan Stanley | |
| MM3GSK | | Halozyme Therapeutics Inc./OS/Call [95]/MS | - | - | 95,000 | call | Halozyme Therapeutics Inc. | - | 50,091 % | 0,401 | -0,023 | 5,238 | 18.12.2026 | 0,100 | Morgan Stanley | |
| MN2Z3C | | Halozyme Therapeutics Inc./OS/Call [95]/MS | - | - | 95,000 | call | Halozyme Therapeutics Inc. | - | - | - | - | - | 17.12.2027 | 0,100 | Morgan Stanley | |
| MN2Z3D | | Halozyme Therapeutics Inc./OS/Call [95]/MS | - | - | 95,000 | call | Halozyme Therapeutics Inc. | - | 57,610 % | 0,288 | -0,036 | 7,869 | 18.09.2026 | 0,100 | Morgan Stanley | |
| MR3CU8 | | Halozyme Therapeutics Inc./OS/Call [95]/MS | - | - | 95,000 | call | Halozyme Therapeutics Inc. | - | 49,854 % | 0,466 | -0,019 | 4,055 | 19.03.2027 | 0,100 | Morgan Stanley | |
| JE111Q | Halozyme Therapeutics Inc./OS/Call [96]/JPMD | - | - | 96,000 | call | Halozyme Therapeutics Inc. | - | 51,770 % | 0,397 | -0,024 | 5,112 | 18.12.2026 | 0,100 | JP Morgan | ||
| JE8Z1R | Halozyme Therapeutics Inc./OS/Call [98]/JPMD | - | - | 98,000 | call | Halozyme Therapeutics Inc. | - | 52,573 % | 0,378 | -0,024 | 5,144 | 18.12.2026 | 0,100 | JP Morgan | ||
| MM26RY | | Halozyme Therapeutics Inc./OS/Put [50]/MS | - | - | 50,000 | put | Halozyme Therapeutics Inc. | - | 72,867 % | -0,131 | -0,010 | 2,051 | 17.06.2027 | 0,100 | Morgan Stanley | |
| MM26RZ | | Halozyme Therapeutics Inc./OS/Put [50]/MS | - | - | 50,000 | put | Halozyme Therapeutics Inc. | - | 83,816 % | -0,110 | -0,016 | 3,042 | 18.12.2026 | 0,100 | Morgan Stanley | |
| MN5C5Y | | Halozyme Therapeutics Inc./OS/Put [50]/MS | - | - | 50,000 | put | Halozyme Therapeutics Inc. | - | 81,845 % | -0,146 | -0,009 | 1,193 | 17.12.2027 | 0,100 | Morgan Stanley | |
| MN6G49 | | Halozyme Therapeutics Inc./OS/Put [50]/MS | - | - | 50,000 | put | Halozyme Therapeutics Inc. | - | 75,166 % | -0,121 | -0,012 | 2,498 | 19.03.2027 | 0,100 | Morgan Stanley | |
| JE0LBK | Halozyme Therapeutics Inc./OS/Put [64]/JPMD | - | - | 64,000 | put | Halozyme Therapeutics Inc. | - | 74,272 % | -0,152 | -0,030 | 5,771 | 18.09.2026 | 0,100 | JP Morgan |